The Global Migraine Market to Surpass USD 6.5 Billion Mark by 2032, asserts DelveInsight

The Global Migraine Market to Surpass USD 6.5 Billion Mark by 2032, asserts DelveInsight
Migraine Market
DelveInsight’s Migraine Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options.

DelveInsight’s Migraine Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. 

The report also covers Migraine epidemiology, emerging therapeutics, market dynamics, market drivers and barriers, ongoing clinical trials, important collaborations in the field, and key pharmaceutical companies actively pushing market growth forward for the study period 2018-2030 in 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Some of the key highlights from the Migraine Market Insights

  • The World Health Organization’s disability rating for migraine ranks it as the 19th most common reason for disability.
  • According to the Migraine Trust Organization, migraine is the world’s seventh most debilitating condition (accounting for 2.9 percent of all years of life lost to disability/YLDs) and the leading cause of disability of all neurological disorders.
  • According to the Migraine Research Foundation, migraine is a very common neurological condition. Migraine affects about 39 million Americans and one billion people worldwide.
  • Key players, such as Axsome Therapeutics, Impel NeuroPharma, Zosano Pharma Corporation, and many others, are involved in developing therapies for migraine. 
  • Emerging therapies such as INP104 (Impel NeuroPharma), AXS-07 (Axsome Therapeutics), M207/ADAM Zolmitriptan (Zosano Pharma Corporation), and others are expected to have a significant impact on the migraine market in the coming years.

Learn more by requesting for sample @ Migraine Market Landscape 

Migraine: Overview 

Migraine is a neurological condition involving nerve pathways and chemicals in the brain. It is one of the most common and widespread neurological disorders with extremely incapacitating neurological symptoms. It is inconsistent in how the brain interacts with incoming sensory input, and that uncertainty can be affected by physiological changes, including sleep, exercise, and hunger.

It consists of an intense throbbing habitual ache, commonly on one aspect of the head, regularly observed through visible disturbances, nausea, vomiting, dizziness, excessive sensitivity to sound, light, contact, and smell, and tingling or numbness withinside the extremities or face; even though signs commonly consist of an intense throbbing habitual ache on one aspect of the head, but in one-1/3 of migraine attacks, each facet are located to be affected.

Migraine is categorized as acute, chronic, or episodic migraine based on the severity of the attack and its frequency. Migraine sufferers with 0 to 14 headache days per month have episodic migraine, while chronic migraine sufferers have 15 or more headache days per month. Every year, about 2.5 percent of episodic migraine patients experience new-onset chronic migraine.

Migraine is more common in boys than in girls before puberty. Because of hormonal shifts, the frequency and prevalence of migraine in girls increase more rapidly than in boys as puberty approaches.

For more insights into Disease, causes and treatment, reach out @ Migraine Treatment Landscape 

Migraine Epidemiology Segmentation 

The Migraine Market report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Migraine Prevalence 
  • Age-Specific Migraine Prevalence 
  • Gender-Specific Migraine Prevalence 
  • Diagnosed and Treatable Cases of Migraine

Migraine Market 

The launch of various innovative medicines, important firms operating in the area, rising prevalence, more R&D in the area, and medical innovations occurring in the Migraine market domain are all projected to contribute to the market’s growth.

Migraine Pipeline Therapies and Key Companies 

  • INP104: Impel NeuroPharma
  • AXS-07: Axsome Therapeutics
  • M207/ADAM Zolmitriptan: Zosano Pharma Corporation

For more information, visit Migraine Market Analysis, Patient Pool and Emerging Therapies 

Table of Contents 


Key Insights


Report Introduction


Competitive Intelligence Analysis for Migraine


Migraine Market Overview at a Glance


Executive Summary of Migraine


Migraine Epidemiology and Market Methodology


Migraine Epidemiology and Patient Population


Migraine Patient Journey


Treatment Algorithm, Current Treatment, and Medical Practices


Key Endpoints in Migraine Clinical Trials


Migraine Marketed Therapies 


Migraine Emerging Therapies


Migraine: 7 Major Market Analysis


Attribute analysis


Access and Reimbursement Overview of Migraine


KOL Reviews


Case Reports


Migraine Market Drivers


Migraine Market Barriers


SWOT Analysis




DelveInsight Capabilities


About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States